Clinical trials: Pulmonary Disease, Chronic Obstructive
Pulmonary Emphysema
Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion
Prospective, multi-centre, pilot study aimed to evaluate the effect of Video Assisted Thoracic Surgery (VATS) fissure completion on the efficacy of endobronchial valve insertion (Zephyr Valve) in the treatment of subjects with…
- Trial name
- COVE (NCT04465461)
- Testing
- Video-assisted thoracoscopic surgery (VATS) fissure completion, Zephyr Valve insertion
- Where
- 2 sites in Australia
- Volunteers
- 9 people
- Sponsor
- Pulmonx Corporation
Pulmonary Disease, Chronic Obstructive
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
The real world study aims to assess effectiveness and safety profile between tiotropium/olodaterol (Tio/Olo) and inhaled corticosteroids(ICS) / Long-acting β2-agonists (LABA) in patients with chronic obstructive pulmonary disease…
- Trial name
- NCT05402020
- Testing
- Tiotropium (Tio), Inhaled corticosteroids (ICS), Olodaterol (Olo)
- Where
- China
- Volunteers
- 17,018 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Japan Long-term Safety for Tiotropium Plus Olodaterol
The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic…
- Trial name
- NCT01536262
- Testing
- Tiotropium + Olodaterol, Respimat, Olodaterol
- Where
- 24 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Acute Bronchitis, Acute Exacerbations of Chronic Bronchitis
A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
The purpose of this study is to determine the optimal dose of HL301 in patients with acute bronchitis or acute exacerbations of chronic bronchitis.
- Trial name
- HL301 (NCT02250027)
- Testing
- HL301 300mg capsule
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD
Study investigating the safety, tolerability, pharmacokinetics and early efficacy with KIT2014 over 7 days of treatment in moderate to severe chronic obstructive pulmonary disease patients.
- Trial name
- NCT07668518
- Testing
- KIT2014
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- Kither Biotech Srl
Chronic Obstructive Pulmonary Disease
Evaluation the Safety of hemay005 Tablets
Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.
- Trial name
- NCT06908642
- Testing
- Hemay005 tablet
- Where
- China
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- Anhui Hemay Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02233686
- Testing
- XEN-D0501
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Xention Ltd
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Chronic Obstructive Pulmonary Disease
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
- Trial name
- AERIFY-3 (NCT05326412)
- Testing
- Itepekimab SAR440340
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00796653
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 98 sites in Argentina, Brazil and 18 more
- Volunteers
- 937 people
- Sponsor
- Boehringer Ingelheim
Copd
Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001
To evaluate systemic pharmacokinetics of CHF6001 following concomitant administration of CHF6001 and CHF5259, in comparison with the single components, administered in healthy subjects via a multi-dose reservoir NEXThaler® DPI.
- Trial name
- NCT03004495
- Testing
- CHF5259 and CHF6001
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
A study to evaluate the effects of ACT-541468 on respiration in patients with moderate chronic obstructive pulmonary disease
- Trial name
- NCT03646864
- Testing
- ACT-541468
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Emphysema
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8 subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00435253
- Testing
- BLVR Treatment
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aeris Therapeutics
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
- Trial name
- NCT01039675
- Testing
- 500mcg/25mcg once daily
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
The prevalence, low cost, and low burden of wearable devices that provide quantitative and qualitative feedback on a subject's activity level present an opportunity for the use of these devices in clinical and observational…
- Trial name
- NCT02619357
- Testing
- SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
- Trial name
- NCT02864407
- Testing
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
- Trial name
- NCT00465959
- Testing
- trospium chloride inhalation powder (TrIP)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pulmonary Disease, Chronic Obstructive
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease.
- Trial name
- NCT00453479
- Testing
- GSK233705B
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Hypogonadism, Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive…
- Trial name
- NCT01061970
- Testing
- Fispemifene
- Volunteers
- 15 people
- Sponsor
- QuatRx Pharmaceuticals Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.